Full-Time

National Enterprise Strategic Accounts Manager

Posted on 2/18/2025

Natera

Natera

1,001-5,000 employees

Biotechnology firm specializing in genetic testing

Biotechnology
Healthcare

Compensation Overview

$230k - $250kAnnually

+ Commission Structure

Senior, Expert

Company Historically Provides H1B Sponsorship

United States

Category
Strategic Account Management
Sales & Account Management
Required Skills
Sales
Data Analysis

You match the following Natera's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Bachelor’s degree required; MBA preferred.
  • 5+ years of physician sales experience in diagnostic laboratories (preferably genetics).
  • 3+ years of successful National Health System sales/consulting experience (preferably genetics).
  • Proven success in market development, product launches, and rapid revenue growth.
  • Award-winning sales record with expertise in EMRs and hospital system contracting.
  • Skilled in navigating complex negotiations, including C-suite engagements.
  • Experience in National Health System project planning and strategy execution.
  • Knowledge of Healthcare Value Transformation and Triple Aim Initiatives.
  • Proficient in Google Suite, Microsoft Office, and data reporting/analysis.
Responsibilities
  • Execute an interdepartmental approach to remove existing barriers and open access to all Natera testing across the enterprise.
  • Become an expert in Natera’s technology and service offerings and be able to represent the company and its business interests at the highest levels of leadership within Health Systems.
  • Develop and execute business plans aligned with organizational goals, coordinating cross-functional strategies.
  • Optimize testing workflows and efficiencies to standardize Natera products system-wide.
  • Implement strategic account plans and best practices based on field insights, market assessments, and trends.
  • Identify and manage RFP, GPO, and contracting opportunities within major health systems.
  • Develop scalable, long-term partnership solutions for National Accounts.
  • Effectively work with Natera team members in order to help maximize potential business opportunities and partnerships.
  • Establish positive working relationships with all key customer segments (internal and external).
  • Maintain an active key account List of National Accounts and work with Leadership, Providers, and Total Available Market (TAM) as this segment continues to grow.
  • Identify and regularly meet with National Health System leadership, i.e., ELTs, Medical Directors, Precision Medicine Leaders, CIO, COO, Lab Directors, etc.
  • Allocate time as defined by leadership, in the field with AD’s, RD’s, and SAM’s to provide direction and feedback to maximize potential collaboration opportunities.
  • Identify Natera’s areas of focus to help establish an appropriate road map within National accounts.
  • Travel up to 70% for customer and team engagements.
  • This role works with PHI regularly, both in paper and electronic form, and has access to various technologies to access PHI (paper and electronic) to perform the job.
  • Employee must complete training relating to HIPAA/PHI privacy, General Policies and Procedure Compliance training, and security training as soon as possible but not later than the first 30 days of hire.
  • Must maintain a current status on Natera training requirements.
Desired Qualifications
  • Strategic thinker with proven leadership and execution skills.
  • Results-driven with a strong sense of urgency to drive revenue growth.
  • Skilled in developing and executing strategic business plans for record-breaking success.
  • Highly motivated, team-oriented, and coachable with a strong work ethic.
  • Effective time management, multitasking, and prioritization in fast-paced environments.
  • Strong organization, attention to detail, and presentation skills.
  • Ability to build positive relationships with internal and external stakeholders.
  • Thrives under pressure, meeting deadlines with minimal guidance.
  • Works independently while excelling in cross-functional team settings.
  • Desire to play a critical role in the success of the organization.
  • Strong work ethic with the will to succeed.

Natera focuses on genetic testing and diagnostics, utilizing cell-free DNA (cfDNA) testing to detect molecular residual disease (MRD) in cancer patients and assess organ health for transplant patients. Their offerings include the Signatera test for cancer and Panorama NIPT for prenatal screening, with a strong emphasis on personalized genetic counseling. Natera stands out by providing a wide range of specialized testing services directly to healthcare providers and patients, often reimbursed by insurance. The company's goal is to improve patient care and health outcomes through advanced genetic testing solutions.

Company Size

1,001-5,000

Company Stage

IPO

Total Funding

$149.9M

Headquarters

Austin, Texas

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased adoption of liquid biopsy techniques boosts demand for Natera's cfDNA tests.
  • Growing personalized medicine trend enhances need for Natera's customized genetic tests.
  • Expansion of telehealth services aligns with Natera's remote genetic counseling offerings.

What critics are saying

  • Allegations of deceptive practices could harm Natera's reputation and lead to legal issues.
  • New Prospera Heart features may face adoption challenges without independent validation.
  • Ongoing legal investigations could result in financial penalties affecting Natera's stability.

What makes Natera unique

  • Natera's Signatera test offers significant lead time in detecting cancer recurrence.
  • Prospera Heart test integrates Donor Quantity Score for enhanced transplant rejection detection.
  • Panorama NIPT uniquely determines fetal RhD status, aiding in prenatal care.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

10%
BioSpace
Feb 19th, 2025
Natera To Report Its Fourth Quarter And Full Year Results On February 27, 2025

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its fourth quarter and year ended Dec. 31, 2024, after the market closes on Feb. 27, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m

MarketBeat
Nov 24th, 2024
Alpha DNA Investment Management LLC Invests $505,000 in Natera, Inc. (NASDAQ:NTRA)

Alpha DNA Investment Management LLC invests $505,000 in Natera, Inc. (NASDAQ:NTRA).

MarketBeat
Sep 22nd, 2024
Delap Wealth Advisory LLC Makes New $454,000 Investment in Natera, Inc. (NASDAQ:NTRA)

Delap Wealth Advisory LLC makes new $454,000 Investment in Natera, Inc. (NASDAQ:NTRA).

Investing.com
Jul 2nd, 2024
Natera CFO sells over $539k in company stock

In other recent news, Natera Inc. has launched the DECIPHER trial for gastroesophageal adenocarcinoma (EGC) treatment, utilizing its molecular residual disease (MRD) test, Signatera.

Yahoo Finance
Jun 17th, 2024
Natera Launches Differentiated New Feature For Prospera(Tm) Heart Test, Enhancing Detection Of Rejection For Transplant Patients

Donor Quantity Score (DQS) technique is unique to Natera, improving detection of both acute cellular rejection and antibody-mediated rejectionAUSTIN, Texas, June 17, 2024--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of Prospera Heart™ with Donor Quantity Score (DQS), further enhancing Prospera’s ability to detect rejection in heart transplant patients.Traditionally, donor-derived cell-free DNA (dd-cfDNA) tests have reported rejection risk based only on the fraction of dd-cfDNA in the blood vs. the total cfDNA (dd-cfDNA %). This fraction can be confounded by fluctuations in the amount of background total cfDNA (the denominator), which are sometimes caused by factors unrelated to the health of the transplant, including infection, surgery, or chemotherapy.Prospera Heart now incorporates a second metric – the DQS – that normalizes for the background total cfDNA. Prospera Heart with DQS combines the traditional donor fraction and the new DQS into a two-threshold algorithm, delivering a single result with more accurate risk assessment for both antibody mediated rejection (AMR) and acute cellular rejection (ACR)."Over the last two decades, Natera has pioneered cfDNA testing across women’s health, oncology, and transplant medicine," said Michael Olymbios, M.D., Medical Director, Heart Transplant. "Our extensive experience with cfDNA and Natera’s culture of continuous innovation drove us to further refine Prospera Heart by introducing this two-threshold algorithm to better serve the transplant community."A study performed at the University of Utah and the University of California San Diego showed that incorporating DQS enhanced the performance of Prospera Heart in screening for biopsy-proven active rejection